期刊文献+

TRAF3在肝细胞肝癌中的表达及意义 被引量:3

Significance of TRAF3 protein expression in hepatocellular carcinoma
下载PDF
导出
摘要 目的探讨肿瘤坏死因子受体相关因子3(TRAF3)在肝细胞癌(简称肝癌)发生、发展中的意义。方法采用免疫组化方法检测50例原发性肝癌组织、12例癌旁肝组织及10例正常肝组织中TRAF3蛋白的表达,分析其与肝癌的临床病理参数的关系。Western blot法检测TRAF3在肝癌高分化细胞系HepG2、低分化细胞系SMMC7721和人正常肝细胞系L-02中的表达差异。结果 TRAF3主要定位于细胞质,其阳性率在正常肝组织(100%)及癌旁组织(91%)明显高于肝细胞癌组织(52%)。TRAF3在肝癌的表达与临床分期相关,与患者性别、年龄、癌灶数目、肿瘤大小、瘤栓有无、乙肝表面抗原(HBsAg)阴阳性、甲胎蛋白(AFP)、肿瘤包膜是否完整均无关。TRAF3总蛋白在正常肝细胞系中的表达量明显高于肝癌细胞系,且在肝癌高分化的细胞系中表达量高于低分化细胞系。结论 TRAF3在肝癌中的表达明显下调,且在肝癌中的表达水平与肝癌的侵袭程度相关,提示TRAF3可能抑制肝癌的浸润和转移。 Objective To study the significance of tumor necrosis factor receptor associated factor 3(TRAF3) in the carcinogenesis and development of hepatocellular carcinoma(HCC).Methods The expressions of TRAF3 in 50 HCC specimens,12 carcinoma tissue specimens and 10 normal hepatic tissue specimens were detected by immunohistochemistry.The expressions of TRAF3 in HCC well-differentiated cells HepG2,poorly differentiated cells SMMC7721 and human normal liver cells L-02 were detected by Western blot.Results TRAF3 was mainly expressed in cytoplasm.The positive rate of TRAF3 in normal liver tissues(100%) and adjacent normal tissues(91%) were significantly higher than that in HCC(52%).Expression of TRAF3 was related to clinical stage,while not related to sexuality,age,the number of cancers,size,tumor embolus,HBsAg,AFP and tumor capsule.The protein level of TRAF3 was obviously higher in L-02 normal liver cells than that in HCC and it was slightly higher in HepG2 cells than that in SMMC7721 cells.Conclusion The expression of TRAF3 in HCC is suppressed,and correlative to the invasive ability of HCC.These results suggest that TRAF3 can inhibit invasion and metastasis in HCC.
出处 《安徽医科大学学报》 CAS 北大核心 2012年第8期952-955,共4页 Acta Universitatis Medicinalis Anhui
基金 国家重大科学研究计划(973计划)资助项目(编号:2011CB910600)
关键词 肿瘤坏死因子受体相关因子3 原发性肝细胞癌 侵袭转移 TRAF3; hepatocellular carcinoma; invasion
  • 相关文献

参考文献12

  • 1Ramakrishnan P, Wang W, Wallach D. Receptor-specific signa- ling for both the alternative and the canonical NF-KB activation pathways by NF-KB-inducing kinase[J]. Immunity ,2004,21 (4) : 477 - 89.
  • 2Dempsey P W, Doyle S E, He J O, et al. The sigaling adaptors and pathways activated by TNF superfamily[ J]. Cytokine Growth Factor Rev,2003,14 (3 - 4 ) : 193 - 209.
  • 3He J Q, Saha S K, Kang J R, et al. Specificity of TRAF3 in its negative regulation of the noncanonical NF-KB pathway[J]. J Biol Chem,2007,282 (6) :3688 - 94.
  • 4Bilotas M, Baranao R I, Buquet R, et al. Effect of GnRH analogues on apoptosis and expression of Bcl-2, Bax, Fas and FasL proteins inendometrial epithelial cell cultures from patients with endometrio- sis and controls [ J ]. Hum Reprod ,2006.22 ( 3 ):644 - 53.
  • 5Varfolomeev E. IAP antagonists induce autoubiquitination of cIAPs NF-KB activation, and TNFα-depend apoptosis [ J ]. Cell, 2007,131 (4) :669 -81.
  • 6Vince J E. IAP antagonists target cIAP1 to induce TNFα depend- ent apoptosis [ J ]. Cell ,2007,131 (4) :682 - 93.
  • 7Gardam S. TRAF2 and TRAF3 signal adapters act cooperatively to control the maturation and survival signals delivered to B cells by the BAFF receptor[J]. Immunity,2008,28(3) :391 -401.
  • 8He J Q. Rescue of TRAF3-null mice by pl00 NF-KB deficiency [ J]. J Exp Med,2006,203 ( 11 ) :2413 - 18.
  • 9McCarty M F, Block K I. Preadministration of high-dose salicy- lates, suppressor of NF-kappaB activation, may increase the chemo- sensitvity of many cancers : an example of proapoptotic signal mod- ulation therapy [ J ]. Integr Cancer Ther,2006, 5 ( 3 ) :252 - 68.
  • 10Keats J ], Fonseca R,Chesi M,et al. Promiscuous mutations acti- vate the NF-κB noncanonical pathway in multiple myeloma [ J ]. Cancer Ce11,2008,12(2) : 131 -44.

同被引文献23

  • 1许良中,杨文涛.免疫组织化学反应结果的判断标准[J].中国癌症杂志,1996,6(4):229-231. 被引量:1363
  • 2Cuadrado A,Nebreda AR.Mechanisms and functions of p38MAPK signalling[J].Biochem,2010,429(3):403-417.
  • 3Cuadrado A,Nebreda AR.Mechanisms and functions of p38MAPK signalling[J].Biochem,2010,429(3):403-417.
  • 4Bradley JR,Pober JS.Tumor necrosis factor receptor-associated factors(TRAFs)[J].Oncogene,2001,20(44):6482-6491.
  • 5Casanovas O,Miró F,Estanyol JM,et al.Osmotic stress regulates the stability of cyclin D1 in a p38SAPK2-dependent manner[J].Biol Chem,2000,275(45):35091-35097.
  • 6Phong MS,Van Horn RD,Li S,et al.p38 mitogen-activated protein kinase promotes cell survival in response to DNA damage but is not required for the G(2) DNA damage checkpoint in human cancer cells[J].Mol Cell Biol,2010,30(15):3816-3826.
  • 7Mikhailov A,Shinohara M,Rieder CL.Topoisomerase Ⅱ and histone deacetylase inhibitors delay the G2/M transition by triggering the p38 MAPK checkpoint pathway[J].Cell Biol,2004,166(4):517-526.
  • 8Bulavin DV,KovalskyO,Hollander MC,et al.Loss of oncogenic H-ras-induced cell cycle arrest and p38 mitogen activated protein kinase activation by disruption of Gadd45a[J].Mol Cell Biol,2003,23(11):3859-3871.
  • 9Vitale I,Senovilla L,Galluzzi L,et al.Chk1 inhibition activates p53 through p38 MAPK in tetraploid cancer cells[J].Cancer,2008,7(13):1956-1961.
  • 10Park SJ,Kim IS.The role of p38 MAPK activation in auranofin-induced apoptosis of human promyelocytic leukaemia HL-60 cells[J].Br J Pharmacol,2005,146(4):506-513.

引证文献3

二级引证文献7

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部